May 09, 2019 Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
May 01, 2019 Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
Apr 03, 2019 Checkpoint Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Mar 15, 2019 Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
Jan 07, 2019 Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
Nov 02, 2018 Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Sep 25, 2018 Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101